Serum non-invasive testing scores and modeling to predict intermediate or high risk for advanced fibrosis due to metabolic dysfunction-associated steatotic liver disease (MASLD) in a type 2 diabetes population cohort.
Arndt, G., Lindsay, M., Swartwood, S., Arrigain, S., Lopez Moscoso, R., Wieland, A., & Jensen, T.